Abstract
The pharmacological properties of nativeN-methyl-d-aspartate (NMDA) receptors were determined in rat brain sections with quantitative autoradiography of [3H](E)-2-amino-4-propyl-5-phosphono-3-pentenoic acid (CGP39653) binding. With five competitive antagonists as displacers, two subpopulations of binding sites were observed in the horizontal plane of section examined. These two populations corresponded anatomically to NR2A and NR2B subunits. Quantitative analysis of NR2A-like and NR2B-like binding sites was enabled by examining the cerebellar granule cell layer, which expresses NR2A and NR2C subunits, and the medial striatum, which predominately expresses NR2B subunits. The antagonists (R)-(E)-4-(3-phosphonoprop-2-enyl)piperazine-2-carboxylic acid and (R)-2-amino-5-phosphonopentanoate (d-AP5) displayed similar affinities at cerebellar NMDA receptors and medial striatal NMDA receptors. In contrast, the NMDA receptor antagonists (±)-6-(1H-Tetrazol-5-ylmethyl)decahydroisoquinoline-3-carboxylic acid, (S)-α-amino-5-(phosphonomethyl)[1,1′-biphenyl]-3-propanoic acid, and (±)-cis-4-(4-phenylbenzoyl) piperazine-2,3-dicarboxylic acid displayed varied, higher affinities at medial striatal NMDA receptors than at cerebellar NMDA receptors. For the five antagonists, there was a strong correlation (r = 0.9) between the cerebellarKi/medial striatumKi ratio and the NR2AKi/NR2B Ki ratio for recombinant receptors. Thus, [3H]CGP39653 labels two pharmacologically distinct populations of NMDA receptors that have pharmacological and anatomical properties consistent with NR2A and NR2B subunits. Because native NR2A- and NR2B-containing receptors are pharmacologically distinct, it should be possible to develop NR2A- and NR2B-selective glutamate site antagonists.
Footnotes
-
Send reprint requests to: Dr. Daniel T. Monaghan, Department of Pharmacology, 986260 Nebraska Medical Center, Omaha, NE 68198-6260. E-mail: dtmonagh{at}unmc.edu
-
↵1 This work was supported by United States Army Medical Research contract DAMD17-94-C-4050 (to D.T.M. and Jeff Watkins) and by the Medical Research Council (to D.E.J.).
-
↵2 Current address: Vollum Institute, Oregon Health Sciences University, 3181 SW Sam Jackson Park Rd., Portland, OR 97201.
- Abbreviations:
- NMDA
- N-methyl-d-aspartate
- CGP39653
- (E)-2-amino-4-propyl-5-phosphono-3-pentenoic acid
- PBPD
- (±)-cis-4-(4-phenylbenzoyl) piperazine-2,3-dicarboxylic acid
- d-AP5
- (R)-2-amino-5-phosphonopentanoate
- LY233536
- (±)-6-(1H-Tetrazol-5-yl-methyl)decahydroisoquinoline-3-carboxylic acid
- EAB515
- (S)-α-amino-5-(phosphonomethyl)[1,1′-biphenyl]-3-propanoic acid
- d-CPPene
- (R)-(E)-4-(3-phosphonoprop-2-enyl)piperazine-2-carboxylic acid
- CPP
- (±)-2-carboxypiperazine-4-yl-propyl-1-phosphonic acid
- Received September 23, 1999.
- Accepted November 16, 1999.
- The American Society for Pharmacology and Experimental Therapeutics
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|